|
gptkbp:instanceOf
|
LSD
amphetamine
Hallucinogen
|
|
gptkbp:actsOn
|
5-HT2A receptor agonist
|
|
gptkbp:appearance
|
white powder
|
|
gptkbp:aroma
|
odorless
|
|
gptkbp:CASNumber
|
1227608-02-7
|
|
gptkbp:chemicalFormula
|
C18H22ClNO3
|
|
gptkbp:discoveredBy
|
gptkb:Ralf_Heim
|
|
gptkbp:discoveredIn
|
2003
|
|
gptkbp:duration_of_effect
|
6-10 hours
|
|
gptkbp:excretion
|
kidneys
|
|
gptkbp:first_identified_in
|
designer drug market
|
|
gptkbp:hasStreet
|
Cimbi-82
NBOMe-2C-C
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
25C-NBOMe
|
|
gptkbp:IUPACName
|
2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine
|
|
gptkbp:legalStatus
|
gptkb:Class_A_(UK)
Schedule I (USA)
illegal (many countries)
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
335.83 g/mol
|
|
gptkbp:not_detected_by
|
standard drug tests
|
|
gptkbp:not_used_as
|
gptkb:medicine
|
|
gptkbp:relatedTo
|
gptkb:25B-NBOMe
gptkb:25I-NBOMe
gptkb:2C-C
|
|
gptkbp:researched_for
|
brain imaging (PET ligand)
|
|
gptkbp:riskFactor
|
overdose
misidentification as LSD
|
|
gptkbp:routeOfAdministration
|
sublingual
nasal
buccal
|
|
gptkbp:sells
|
tablets
powder
blotters
|
|
gptkbp:sideEffect
|
hypertension
seizures
hallucinations
death (in overdose)
vasoconstriction
|
|
gptkbp:toxicity
|
high (compared to other psychedelics)
|
|
gptkbp:usedFor
|
recreational drug
|
|
gptkbp:bfsParent
|
gptkb:NBOMe_series
|
|
gptkbp:bfsLayer
|
7
|